Analytical Data
-
Gene name
FITC-Labeled VEGF165
-
简介
VEGF165 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. FITC-Labeled VEGF165 Protein, Human (HEK293, C-His) is the recombinant human-derived FITC-Labeled VEGF165 protein, expressed by HEK293 , with C-His, C-Avi labeled tag. The total length of FITC-Labeled VEGF165 Protein, Human (HEK293, C-His) is 165 a.a., with molecular weight of 27-33 kDa.
- Application
-
Alternative Names
RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P15692-4
-
Expression Region
A27-R191
-
Protein Length
Partial
-
Molecular Weight
28-33 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular endothelial growth factor (VEGF) is a key signaling protein that plays a critical role in angiogenesis, promoting the formation of new blood vessels. Among its isoforms, VEGF165 is particularly significant due to its strong mitogenic effects on endothelial cells and its involvement in various physiological and pathological processes, including wound healing, tumor growth, and inflammation. The use of FITC (fluorescein isothiocyanate) labeling allows researchers to visualize and track VEGF165 interactions in real time, facilitating the study of its distribution and dynamics in various biological contexts. Understanding the binding affinity and specificity of FITC-labeled VEGF165 to its receptors, such as VEGFR-1 and VEGFR-2, can provide insights into the molecular mechanisms underlying angiogenesis and potential therapeutic targets for conditions like cancer and cardiovascular diseases. The development and characterization of FITC-labeled VEGF165 recombinant proteins thus represent a crucial step in advancing the understanding of angiogenic processes, enabling researchers to explore the multifaceted roles of VEGF165 in health and disease, while also enhancing the discovery of novel treatment strategies leveraging anti-angiogenic therapies.
